Liberty Global Using Vecima Automation Solutions to Drive Network Simplification and Efficiency
29.9.2025 14:30:00 EEST | Business Wire | Press release
Vecima Networks Inc. (TSX:VCM) announced today that Liberty Global (NASDAQ: LBTYA, LBTYB, and LBTYK), one of the world’s leading converged video, broadband, and communications companies, is advancing its network innovation strategy by working with Vecima’s Entra® Access Test Platform. Positioned to play a pivotal role in Liberty Global’s approach to next-generation broadband, the platform delivers powerful, production-scale testing capabilities that align with Liberty Global’s evolving objectives and unlock further opportunities for technology adoption across its ecosystem.
Purpose-built to replicate production-scale environments and streamline testing workflows, the Entra Access Test Platform enables operators to perform comprehensive, high-fidelity testing of Converged Multi-Access Network technologies, including virtual Cable Modem Termination Systems (vCMTS). Proven in collaboration with other Tier 1 operators deploying third-party cores and validated with Vecima’s own Entra product portfolio, the platform delivers exceptional interoperability, reliability, and performance assurance across the broadband access landscape.
“Partnering with an industry leader like Vecima represents a strategic advancement in how we approach network validation and integration,” said Colin Buechner, Managing Director and Chief Network Officer at Liberty Global. “It not only strengthens our deployment capabilities but also plays a critical role in establishing a common, vendor-neutral testing framework that is rapidly becoming the industry standard. It’s a significant milestone for the cable sector—fostering greater interoperability, accelerating innovation, and delivering shared value across the entire ecosystem.”
“Vecima continues to lead the charge in advancing Distributed Access Architecture (DAA) solutions, supporting operators globally as they evolve their networks,” said Ken Kerwin, Group Vice President at Vecima. “Our work alongside Liberty Global highlights a shared vision for enabling operators to address complex, real-world network challenges with precision. Operators who want their transition to vCMTS to be as reliable as current CCAP deployments realize the need for implementing automated and scalable testing enabled by the Entra Access Test Platform.”
The growing momentum behind the Entra Access Test Platform was amplified by Vecima’s strategic acquisition of Falcon V Systems in October 2024. By leveraging Falcon V’s deep automation expertise and expanding R&D capabilities across Europe, Vecima continues to drive the development of scalable, vendor-agnostic solutions. This synergy not only enhances Vecima’s global broadband leadership but also accelerates the industry’s journey toward greater standardization and interoperability.
Learn more about Entra Automation Solutions, Entra Access Test Platform and Entra Access Simulators on Vecima.com.
Join Vecima at SCTE TechExpo 2025 in Booth A132
September 30 – October 1, Walter E. Washington Convention Center, Washington, D.C.
About Liberty Global
Liberty Global (NASDAQ: LBTYA, LBTYB, and LBTYK) is a dynamic team of operators and investors generating and delivering shareholder value through the strategic management of three platforms — Liberty Telecom, Liberty Growth, and Liberty Services.
Liberty Telecom is a world leader in converged broadband, video and mobile communications services, delivering next-generation products through advanced fiber and 5G networks. Liberty Telecom currently provides approximately 80 million* connections through some of Europe’s best-known consumer brands, including Virgin Media O2 (VMO2) in the U.K., VodafoneZiggo in the Netherlands, Telenet in Belgium and Virgin Media in Ireland. With our substantial scale and commitment to innovation, we are building Tomorrow’s Connections Today, investing in the infrastructure and platforms that empower our customers to make the most of the digital revolution, while deploying the advanced technologies that nations and economies need to thrive.
Liberty Telecom's consolidated businesses generate annual revenue of approximately $3.6 billion, while VMO2 and VodafoneZiggo (nonconsolidated joint ventures) generate combined annual revenue of more than $18 billion.**
Liberty Growth invests, grows and rotates capital into scalable businesses across the technology, media/content, sports and infrastructure industries with a portfolio of approximately 70 companies and various funds, including stakes in companies like ITV, Televisa Univision, Plume, EdgeConneX and AtlasEdge, as well as our controlling interest in the Formula E racing series. Liberty Services delivers innovative technology and finance services, generating approximately $600 million in revenue.***
* Represents aggregate consolidated and 50% owned nonconsolidated fixed and mobile subscribers. Includes wholesale mobile connections of VMO2 and B2B fixed subscribers of VodafoneZiggo. Telenet, VMO2 and VodafoneZiggo deliver mobile services as mobile network operators. Virgin Media Ireland delivers mobile services as a mobile virtual network operator through third-party networks.
**Revenue figures above are provided based on full year 2024 Liberty Global consolidated results and the combined as reported full year 2024 results for VodafoneZiggo and full year 2024 U.S. GAAP results for VMO2.
***Represents full year 2024 revenue of Liberty Services, substantially all of which is derived from our consolidated businesses and nonconsolidated joint ventures.
For more information, please visit www.libertyglobal.com.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at vecima.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding Vecima’s business strategies and objectives, and the anticipated benefits, performance, capabilities, availability, or adoption of its products and services. Such statements reflect current expectations and assumptions about future events and are subject to risks and uncertainties. Vecima undertakes no obligation to update any forward-looking statements unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250929473247/en/
Contacts
Liberty Global
Investor Relations
Michael Bishop +44 20 8483 6246
Corporate Communications
Bill Myers +1 303 220 6686
Matt Beake +44 20 8483 6428
Vecima Networks
Investor Relations: 250-881-1982, invest@vecima.com
Media Relations: bernadette.dunn@vecima.com
Vecima Sales: sales@vecima.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom